| Patient | Charles Darwin |
|---|---|
| Date of birth | 1986-02-12 |
| Identifiers | MRN HR-NI003-SYN; SSN (made up) 000-03-2967 |
| Document date | 2026-09-08 |
| Author | Bernard Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review of cyclic vomiting syndrome. [S]
Mr. Darwin returns after three months at amitriptyline 75 mg at bedtime. He has had one episode in that time, three weeks ago, after an overnight journey with little sleep. He used the sumatriptan spray and an ondansetron tablet at the first nausea and trembling, lay down in a dark room, and was well again within about four hours, without vomiting more than twice. He has had no emergency visits. The dry mouth persists, the constipation is better with more fluid and fiber, and the morning grogginess has faded. He walks most days, practices the relaxation breathing most evenings, and has accepted more invitations than in the spring. He still has some wind between episodes, which troubles him less. [S]
| Element | Detail |
|---|---|
| Medicine | Amitriptyline 75 mg at bedtime for three months at the target dose |
| Episodes | One brief episode in three months, after overnight travel, aborted within about four hours |
| Side effects | Dry mouth; constipation improved; grogginess gone |
| Function | Working most days; going out more |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Wind between episodes, less troublesome; one brief episode; constipation improved |
| Ears, nose, mouth, and throat | Positive | Dry mouth |
| Cardiovascular | Negative | No palpitations outside the prodrome; no fainting |
| Psychiatric | Negative | Mood good; worry about episodes much less; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amitriptyline 25 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 2026-04-14 to 2026-04-28 | completed | S |
| Amitriptyline 50 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 2026-04-28 to 2026-05-12 | completed | S |
| Amitriptyline 75 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 2026-05-12 | active | S |
| Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode | One spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a week | Nasal route | 2026-04-14 | active | S |
| Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode | Dissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episode | Oral route | 2026-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-08 | Body height | 183 | cm | S |
| 2026-09-08 | Body weight | 72.9 | kg | S |
| 2026-09-08 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 2026-09-08 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-09-08 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-09-08 | Heart rate | 70 | /min | S |
| 2026-09-08 | Respiratory rate | 14 | /min | S |
| 2026-09-08 | Body temperature | 36.6 | Cel | S |
| 2026-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-08 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 2026-09-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-09-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and relaxed; weight 72.9 kg |
| Cardiovascular | Regular rhythm at 70 per minute; blood pressure 116/72 mmHg |
| Abdomen | Soft and non-tender |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosis | active | provisional | R11.15 | S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory. |
| Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluation | resolved | confirmed | R11.2 | S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D). |
| Common cold, without a vomiting episode; resolved | resolved | confirmed | J00 | S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Episode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed work | Every visit | Completed today | One episode in three months, about four hours, aborted at the prodrome; no emergency visits |
| Examination | Rome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50) | At diagnosis and with any change in pattern | Completed today | Pattern unchanged and milder; no red flags |
| Laboratory | Blood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serology | At diagnosis between episodes; repeat only for an atypical episode | Up to date | Normal at diagnosis; no atypical episode |
| Imaging | Upper endoscopy and small-bowel imaging (CT enterography) | Once at diagnosis | Up to date | Normal at diagnosis |
| Imaging | Gastric emptying study | Not routine; only between episodes when gastroparesis is suspected | Not indicated | No symptoms of gastroparesis |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Up to date | QTc 436 ms at 75 mg three months ago; repeat only with a dose change or a new QT-prolonging medicine |
| Medication safety | Amitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weight | Each visit on treatment | Completed today | Dry mouth persists; constipation and grogginess improved; weight 72.9 kg (up 1.5 kg since starting) |
| Survey | Mood and thoughts of self-harm on a tricyclic (PHQ-9) | Each visit on treatment | Completed today | PHQ-9 3, with item 9 scored 0 |
| Survey | Anxiety screen (GAD-7) | At diagnosis, then every three months | Completed today | GAD-7 5, down from 8 at the first visit |
| Medication safety | Abortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limits | Every visit | Completed today | Used once, at the prodrome, with relief in about four hours; within dose limits |
| Self-management | Individualized emergency department protocol letter | At diagnosis; update with any change in treatment | Up to date | Letter carried; no change in treatment, so no update needed |
| Self-management | Triggers: sleep, meals, travel, social stress, infections | Every visit | Completed today | Overnight travel with short sleep triggered the one episode; a travel plan agreed |
| Self-management | Cannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome) | At diagnosis and yearly | Up to date | No cannabis use; recheck yearly |
| Examination | Comorbidities: migraine, orthostatic and autonomic symptoms, sleep disorders | At diagnosis and yearly | Up to date | No migraine, orthostatic symptoms, or sleep disorder |
| Medication safety | Mitochondrial supplements (coenzyme Q10, riboflavin) | Conditional; consider with a partial response | Not indicated | Good response to amitriptyline |
| Medication safety | Alternative prophylaxis (topiramate or aprepitant) | Only if amitriptyline fails or is not tolerated | Not indicated | Amitriptyline effective and tolerated |
| Self-management | Relaxation training, meditation, or biofeedback; cognitive behavioral therapy offered | Ongoing | Completed today | Breathing practice most evenings; he does not want cognitive behavioral therapy now, and the offer stays open |
| Examination | Weight and hydration | Every visit | Completed today | 72.9 kg; well hydrated |
Goal progress:
Guideline basis: Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019); Anxiety Disorders in Adults: Screening (2023)
Follow-up: Review in three months; at one year, discuss a slow taper of amitriptyline if he stays well. [S]